Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
DNA repair pathways in cancer therapy and resistance
L Li, Y Guan, X Chen, J Yang, Y Cheng - Frontiers in pharmacology, 2021 - frontiersin.org
DNA repair pathways are triggered to maintain genetic stability and integrity when
mammalian cells are exposed to endogenous or exogenous DNA-damaging agents. The …
mammalian cells are exposed to endogenous or exogenous DNA-damaging agents. The …
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
Temozolomide (TMZ) was used for the treatment of glioblastoma (GBM) for over a decade,
but its treatment benefits are limited by acquired resistance, a process that remains …
but its treatment benefits are limited by acquired resistance, a process that remains …
Epidemiology and overview of gliomas
ME Davis - Seminars in oncology nursing, 2018 - Elsevier
Objective To present an overview of gliomas, review risk factors, and prognostic and
predictive biomarkers. Data Sources Published manuscripts and textbook chapters …
predictive biomarkers. Data Sources Published manuscripts and textbook chapters …
Advances in glioblastoma therapy: an update on current approaches
Glioblastoma multiforme (GBM) is a primary malignant brain tumor characterized by a high
grade of malignancy and an extremely unfavorable prognosis. The current efficacy of …
grade of malignancy and an extremely unfavorable prognosis. The current efficacy of …
[HTML][HTML] Survival analysis of glioblastoma multiforme
S Witthayanuwat, M Pesee, C Supaadirek… - Asian Pacific journal …, 2018 - ncbi.nlm.nih.gov
Results: Seventy-seven patients with a median age of 53 years (range 4-76 years) showed a
median survival time (MST) of 12 months. In subgroup analyses, the PORT patients revealed …
median survival time (MST) of 12 months. In subgroup analyses, the PORT patients revealed …
[HTML][HTML] Major features of the 2021 WHO classification of CNS tumors
HL Smith, N Wadhwani, C Horbinski - Neurotherapeutics, 2022 - Elsevier
Advances in the understanding of the molecular biology of central nervous system (CNS)
tumors prompted a new World Health Organization (WHO) classification scheme in 2021 …
tumors prompted a new World Health Organization (WHO) classification scheme in 2021 …
Effects of curcumin supplementation on vitamin D levels in women with premenstrual syndrome and dysmenorrhea: a randomized controlled study
L Arabnezhad, M Mohammadifard, L Rahmani… - … medicine and therapies, 2022 - Springer
Background Vitamin D has an established role in female reproduction. There is also
evidence for an association between vitamin D levels and menstrual problems such as …
evidence for an association between vitamin D levels and menstrual problems such as …
Transferrin receptor-targeted nanocarriers: overcoming barriers to treat glioblastoma
MJ Ramalho, JA Loureiro, MAN Coelho, MC Pereira - Pharmaceutics, 2022 - mdpi.com
Glioblastoma multiforme (GBM) is the most common and lethal type of brain tumor, and the
clinically available approaches for its treatment are not curative. Despite the intensive …
clinically available approaches for its treatment are not curative. Despite the intensive …
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a …
Background The DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT)
causes resistance of tumor cells to alkylating agents. It is a predictive biomarker in high …
causes resistance of tumor cells to alkylating agents. It is a predictive biomarker in high …